|
gptkbp:instanceOf
|
gptkb:drug
gonadotropin-releasing hormone antagonist
|
|
gptkbp:approvalYear
|
2008
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
L02BX02
|
|
gptkbp:brand
|
gptkb:Firmagon
|
|
gptkbp:CASNumber
|
214766-78-6
|
|
gptkbp:chemicalFormula
|
C82H103ClN18O16
|
|
gptkbp:contraindication
|
hypersensitivity to degarelix
|
|
gptkbp:developer
|
gptkb:Ferring_Pharmaceuticals
|
|
gptkbp:eliminationHalfLife
|
28 days
|
|
gptkbp:excretion
|
urine
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
degarelix
|
|
gptkbp:isPeptide
|
true
|
|
gptkbp:KEGGID
|
D08916
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
suppresses testosterone production
|
|
gptkbp:metabolism
|
proteolytic degradation
|
|
gptkbp:molecularWeight
|
1632.3 g/mol
|
|
gptkbp:pregnancyCategory
|
X
Not for use in women
|
|
gptkbp:PubChem_CID
|
6918537
DB06663
CHEMBL1201835
|
|
gptkbp:routeOfAdministration
|
subcutaneous injection
|
|
gptkbp:sideEffect
|
weight gain
injection site reactions
hot flashes
increased liver enzymes
|
|
gptkbp:UNII
|
K3G8EEYB0E
|
|
gptkbp:usedFor
|
prostate cancer
|
|
gptkbp:bfsParent
|
gptkb:Firmagon
|
|
gptkbp:bfsLayer
|
8
|